Novel emerging biomarkers to immunotherapy in kidney cancer Review
| Authors: | Ged, Y.; Voss, M. H. |
| Review Title: | Novel emerging biomarkers to immunotherapy in kidney cancer |
| Abstract: | The treatment of metastatic renal cell carcinoma has significantly evolved in recent years, particularly with the advent of novel immune checkpoint inhibitors (ICI). Despite the striking benefits observed on a population level, outcomes vary and some patients do not respond to ICI-based regimens, ultimately require salvage therapies. An ever deeper understanding of the disease biology mediated by the development of multiple high-throughput molecular omics has led to significant progress in biomarkers discovery. But despite growing insights into the molecular underpinnings of the tumor microenvironment, biomarkers have not been integrated successfully into clinical practice. In this review, we discuss some of the novel emerging predictive biomarkers to ICIs in metastatic renal cell carcinoma. © The Author(s), 2021. |
| Keywords: | immunohistochemistry; unclassified drug; overall survival; review; salvage therapy; bevacizumab; sunitinib; clinical practice; cd8+ t lymphocyte; biomarkers; biological marker; dna damage; ipilimumab; progression free survival; anemia; prevalence; interleukin 8; protein; genetic variability; hypercalcemia; angiogenesis; tumor antigen; cancer therapy; renal cell carcinoma; karnofsky performance status; immune response; immunotherapy; perforin; lactate dehydrogenase; kidney cancer; axitinib; cxcl2 chemokine; transitional cell carcinoma; everolimus; cxcl1 chemokine; chemoradiotherapy; cytochrome p450; olaparib; tumor necrosis factor; personalized medicine; programmed death 1 ligand 1; programmed death 1 receptor; non small cell lung cancer; tumor microenvironment; phase 3 clinical trial (topic); phase 1 clinical trial (topic); epithelial mesenchymal transition; rcc; cxcl3 chemokine; cd8alpha antigen; immune checkpoint inhibitor; transcription factor gata 2; nivolumab; immune checkpoint; human; precision medicine; pembrolizumab; network analysis; atezolizumab; avelumab; talazoparib; high throughput analysis; at rich interactive domain containing protein 2; bromodomain containing protein 7; calsequestrin 2; neurexin 3; notch regulated ankyrin repeat protein; polybromo protein 1; protein tyrosine phosphatase receptor type b; receptor activity modifying protein 3 |
| Journal Title: | Therapeutic Advances in Medical Oncology |
| Volume: | 13 |
| ISSN: | 1758-8340 |
| Publisher: | Sage Publications Ltd. |
| Date Published: | 2021-01-01 |
| Language: | English |
| DOI: | 10.1177/17588359211059367 |
| PROVIDER: | scopus |
| PMCID: | PMC8640284 |
| PUBMED: | 34868351 |
| DOI/URL: | |
| Notes: | Review -- Export Date: 3 January 2022 -- Source: Scopus |
